These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 3681449)

  • 1. Biodistribution of indium-111-labeled monoclonal antibodies.
    Hnatowich DJ
    J Nucl Med; 1987 Dec; 28(12):1924-5. PubMed ID: 3681449
    [No Abstract]   [Full Text] [Related]  

  • 2. Radiation absorbed dose estimates for indium-111-labeled B72.3, an IgG antibody to ovarian and colorectal cancer: MIRD dose estimate report No. 18.
    Mardirossian G; Brill AB; Harwood SJ; Olsen J; Dwyer KA; Siegel JA
    J Nucl Med; 1998 Apr; 39(4):671-6. PubMed ID: 9544680
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody.
    Kobayashi H; Wu C; Kim MK; Paik CH; Carrasquillo JA; Brechbiel MW
    Bioconjug Chem; 1999; 10(1):103-11. PubMed ID: 9893971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies.
    Camera L; Kinuya S; Garmestani K; Wu C; Brechbiel MW; Pai LH; McMurry TJ; Gansow OA; Pastan I; Paik CH
    J Nucl Med; 1994 May; 35(5):882-9. PubMed ID: 8176477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro binding to granulocytes of two anti-NCA 95 monoclonal antibodies: Mab1 (ORIS) and Mabgc (Mallinckrodt).
    Collet B; Moisan A; Maros S; Toujas L; Herry JY
    Prog Clin Biol Res; 1990; 355():293-8. PubMed ID: 2281109
    [No Abstract]   [Full Text] [Related]  

  • 6. Radiation dosimetry for indium-111-pentetreotide.
    Stabin MG; Kooij PP; Bakker WH; Inoue T; Endo K; Coveney J; de Jong R; Minegishi A
    J Nucl Med; 1997 Dec; 38(12):1919-22. PubMed ID: 9430470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution.
    Carrasquillo JA; White JD; Paik CH; Raubitschek A; Le N; Rotman M; Brechbiel MW; Gansow OA; Top LE; Perentesis P; Reynolds JC; Nelson DL; Waldmann TA
    J Nucl Med; 1999 Feb; 40(2):268-76. PubMed ID: 10025834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution and dosimetry of indium-111-polyclonal IgG in normal subjects.
    Datz FL; Castronovo FP; Christian PE; Anderson CE; Crebs K; Morton KA; Rauh DA
    J Nucl Med; 1995 Dec; 36(12):2372-9. PubMed ID: 8523134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation doses deriving from patients undergoing 111In-DTPA-D-Phe-1-octreotide scintigraphy.
    Cormack J
    Eur J Nucl Med; 1998 Apr; 25(4):442-4. PubMed ID: 9643971
    [No Abstract]   [Full Text] [Related]  

  • 10. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
    van Schaijk FG; Oosterwijk E; Soede AC; Broekema M; Frielink C; McBride WJ; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodistribution and dosimetry of technetium-99m-hydrazino nicotinamide IgG: comparison with indium-111-DTPA-IgG.
    Callahan RJ; Barrow SA; Abrams MJ; Rubin RH; Fischman AJ
    J Nucl Med; 1996 May; 37(5):843-6. PubMed ID: 8965158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
    van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of biodistribution by introducing different chemical linkages between antibody and an indium-111 chelate.
    Quadri SM; Paik CH; Reba RC; Hong WP
    Cancer Treat Res; 1990; 51():201-13. PubMed ID: 1977445
    [No Abstract]   [Full Text] [Related]  

  • 14. OncoScint image atlas.
    Maguire RT
    Targeted Diagn Ther; 1992; 6():141-75. PubMed ID: 1576344
    [No Abstract]   [Full Text] [Related]  

  • 15. Oncoscint for detection of disseminated colorectal and ovarian cancer.
    Med Lett Drugs Ther; 1993 Jun; 35(898):52-3. PubMed ID: 8497207
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunopharmacokinetics of 111In-CYT-103 in ovarian cancer patients.
    Jusko WJ; Kung LP; Schmelter RF
    Targeted Diagn Ther; 1992; 6():177-90. PubMed ID: 1576345
    [No Abstract]   [Full Text] [Related]  

  • 17. Multicenter clinical trial of 111In-CYT-103 in patients with ovarian cancer.
    Gallup DG
    Targeted Diagn Ther; 1992; 6():111-24. PubMed ID: 1576342
    [No Abstract]   [Full Text] [Related]  

  • 18. Challenges in immunoscintigraphy of ovarian cancer.
    Kim EE; Kasi LP
    Gynecol Oncol; 1993 Mar; 48(3):283-4. PubMed ID: 8462895
    [No Abstract]   [Full Text] [Related]  

  • 19. Lipomas as a potential cause for uptake of In-111 MAb72.3 (Oncoscint CR).
    Sakow NK; Japanwalla M; Tuckson WB; Shields RE
    Clin Nucl Med; 1996 Apr; 21(4):332-3. PubMed ID: 8925626
    [No Abstract]   [Full Text] [Related]  

  • 20. Intense uptake of In-111 satumomab pendetide in an inflammatory mass.
    Silberstein EB; Saeks E
    Clin Nucl Med; 1996 Jan; 21(1):53-5. PubMed ID: 8741891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.